

# **GAVI'S ROLE IN PANDEMIC PREVENTION, PREPAREDNESS AND RESPONSE**

Board Meeting

**Derrick Sim, David Kinder**

26-27 June 2023, Geneva, Switzerland

# Gavi's Role in PPPR

Vaccines are critical in outbreaks, epidemics, pandemics

Alliance is the hub for vaccines and vaccines delivery in global health architecture

Gavi has brought capabilities & contributed to PPPR as part of its core activities:

- Outbreak Response and Prevention
- Vaccine Stockpiles
- Market Shaping for Manufacturing  
Diversification
- Financial Innovation
- Health System Strengthening
- COVAX

## Emerging Key Areas for an Alliance Plan for PPPR

1. Retaining and enhancing capabilities for readiness and response
  - [Global Virtual Pooled Inventory](#) accelerates access to vaccines for emerging / rare diseases
  - Health Care Worker programme protects capabilities for response
  - 'Playbook' for Surge and Operational Capabilities
2. Resilient Health Care Systems and Routine Immunisation (RI) programmes
  - Digital Health Tools strengthen resilience of country health care systems, RI, vaccine traceability
  - Resilience and adaptability to Climate Emergency challenge
3. Diversification of Regional Manufacturing
  - [African Manufacturing '4 Pillar' Strategy](#)
4. Financial innovation
  - [Day Zero Financing Facility](#)

# African Vaccine Manufacturing Accelerator (AVMA)

To achieve AVMA's objectives ...

## 1 Sustainable, regionally diversified supplier base with minimised market distortion

**At least 4** African manufacturers operating sustainably into international markets

**>0.8 billion** doses (Drug Product & Drug Substance) supported over 10 years

## 2 Improved pandemic response capacity, supply resilience and security sovereignty

**3 or more** key drug substance platform technologies localised on the continent

**Substantial** coverage of the African population in an emergency scenario (coverage % variable depending on drug substance platform needed)

... early funding is required

Markets are naturally unpredictable, yet modelled scenarios indicate a foundational requirement of US\$ 0.7 billion – US\$ 1.1 billion

For the incentive to send a strong market signal, we assess an immediate requirement of:

**US\$ 0.7 billion**

## 2023 Timeline

- **June**
  - Alliance deepdives
  - Gavi board update
- **July**
  - Africa CDC deepdive
  - Donor consultations
- **August**
  - Manufacturer roundtables
  - CSO consultations
- **September**
  - Alliance deepdives
  - Donor briefings
- **October**
  - Gavi PPC
  - Africa CDC/AU engagement
- **November**
  - Finalised AMC framework report and investment case
- **December**
  - **Gavi Board for decision**

# Day Zero Pandemic Financing Facility for Vaccines

Comprised of completed and in-development instruments, with completion targeted for end of year

## Day Zero Facility

### Existing donor commitments

#### Pandemic Vaccine Pool (PVP)

- Currently available for COVID-19 use
- Additional use cases for PPPR in discussion target end 2023

### Leveraging existing facilities

#### IFFIm Contingent Financing Mechanism

- Being developed to provide surge financing
- Operational blueprint targeted for December 2023

#### U.S. International Development Finance Corporation (DFC) Rapid Financing Facility

- Available for COVID-19 use
- Additional use for (other) pandemic surge and sustained funding under discussion; finalisation target - December 2023

#### European Investment Bank (EIB) Frontloading Facility

- Operational for surge and sustained financing; can accept contingent grants (amendments for all donors in process)

## Supports each phase of pandemic response

### Phase 1

#### Seed Financing

- Day 1 financing is needed early in a pandemic
  - Cash-in hand
  - Other immediately available resources

### Phase 2

#### Surge Financing

- Secure access to countermeasures & scale delivery from Day 30
  - Repurposed funds
  - Pre-Agreed surge
  - Contingent financing mechanisms
  - Frontloading of early donor pledges and grants

### Phase 3

#### Sustained Financing

- Maintain response capacity to sustain equitable access
  - Reactive fundraising campaigns
  - New resources from multilateral organisations

# Gavi is fully embedded in the conversations on the future global health architecture and ensuring the crucial role of immunisation in PPPR is reflected



- Immunisation is core to PPPR – equity and inclusivity must be built in across all areas.
- Vaccines at the heart of six of the last seven PHEICs
- The Alliance has tried and tested tools across prevention, preparedness and response
- Our programmatic, financial innovation and market-shaping tools have a clear role to play in the new PPPR architecture



Health Working Group & Finance & Health Task Force



Pandemic Treaty & Medical Countermeasures Platform (MCM)




Health and Finance Tracks




Pandemic Fund

# Finding solutions based on PHE archetype challenges



Source: UNICEF Supply Annual Report 2022

# GVPs strengthen Alliance's outbreak response



# Recommendation

Noting that the Secretariat plans to return to the PPC in October 2023 and the Gavi Board in December 2023 with a fully scoped proposal for Gavi in GVPI (Global Virtual Pooled Inventories), which would include, inter alia, confirmation of the role of Gavi and other partners and a financial assessment with a suggested cost envelope, the Gavi Alliance Programme and Policy Committee recommends to the Gavi Alliance Board that it:

**Approve** a time limited envelope until the December 2023 Board meeting of up to US\$ 10 million, for GVPIs for Ebola Sudan and Marburg vaccines if there is a need and an explicit ask from WHO and/or CEPI to Gavi. Any individual agreements with manufacturers would require Phase II data for Ebola Sudan or Marburg candidate vaccines to be available. The individual agreements would be subject to review and approval of Gavi's Market-Sensitive Decisions Committee. This decision would not set a precedent for future Gavi investments.



# Thank you